ClinicalTrials.gg
RecruitingNCT07613359Updated Nov 6, 2026

A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

A Phase 2 interventional study of Mezagitamab and Placebo in Antibody-Mediated Rejection (AMR), sponsored by Takeda. Recruiting at 35 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure. AMR happens when the kidney recipient's immune system makes antibodies that attack the donor kidney. Antibodies are proteins made by the immune system to recognize foreign cells. Over time, this attack can damage kidney tissue and cause the transplant to fail. Because AMR can be serious, there is a need for treatments that are safe, work well, and are supported by good evidence.

The main aim of this study is to find out how safe mezagitamab is and how well adults with AMR tolerate it compared with placebo. A placebo looks like medicine but has no active ingredients. The study will also look at whether mezagitamab helps to control inflammation in the transplanted kidney and helps keep kidney function stable, compared with placebo.

Participants will be placed by chance in 1 of the 3 treatment groups in equal numbers. Two groups will receive mezagitamab in two different doses. One group will receive placebo. This means that out of every 3 participants, 2 will receive mezagitamab and 1 will receive placebo.

During the study, participants will visit their study clinic several times.

02

Conditions studied

  • Antibody-Mediated Rejection (AMR)

Keywords

  • Drug Therapy
  • TAK-079
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. The participant aged 18 to 80 years.
  2. The participant must have a -confirmed diagnosis of active or chronic active late AMR (defined as greater than [>] 6 month after kidney transplant) without concurrent definitive TCMR (Grade 1a and above) as defined by the 2022 Banff classification.
  3. Biopsy within 30 days prior to screening, or performed during screening period within protocol-defined window.
  4. If the participant has received treatment for rejection, then the repeat biopsy and donor specific antibody (DSA) testing must have been performed at least 6 weeks after stopping the treatment.
  5. The participant with either human leukocyte antigen (HLA) class I and/or II DSA.
  6. > 30 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2).

Key exclusion criteria:

  1. The participant has blood type A, B, AB, or O (ABO) incompatible transplant.
  2. The participant has a history of multiple organ transplants, including en bloc and dual kidney transplants.
  3. Participant likely to require renal replacement therapy within the subsequent 30 days.
  4. Participants who have received an anti-cluster of differentiation 38 (CD38) therapy in the last 1 year or have past history of failing to achieve AMR resolution despite treatment with an anti-CD38 therapy.
  5. The participant has received any previous treatment with other or immunomodulatory therapy:

    a) Within 6 months of signing the form (ICF) as listed below:

    • Complement system inhibitors (such as, eculizumab).
    • Proteasome inhibitors (such as, bortezomib).
    • Interleukin-6 (IL-6)/IL-6R antibody (such as, tocilizumab).
    • Anti-cluster of differentiation 20 (CD20) antibody (such as, rituximab). b) Within 6 weeks of signing the ICF as listed below:
    • Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) or plasmapheresis
  6. The participant has active infection with virus, virus (HCV), or (HIV).
  7. Participant with serious infection within 2 weeks or with opportunistic infection within 2 months prior to signing ICF. Participant with active or untreated tuberculosis, or those with high suspicion of tuberculosis are also excluded.
  8. History of (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.

Key Note: Other protocol specified inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Arm A: Mezagitamab + Placebo

    Participants will receive mezagitamab up to Week 24, followed by placebo up to Week 48, followed by an observation period up to Week 70.

    Drug: Mezagitamab · Drug: Placebo

  • Experimental
    Arm B: Mezagitamab

    Participants will receive mezagitamab up to Week 48, followed by an observation period up to Week 70.

    Drug: Mezagitamab

  • Active comparator
    Arm C: Placebo

    Participants will receive placebo up to Week 48, followed by an observation period up to Week 70.

    Drug: Placebo

Interventions

  • Mezagitamab subcutaneous (SC) injection.

    Also known as: TAK-079

  • DrugPlacebo

    Mezagitamab-matching placebo SC injection.

06

What researchers measure

Primary outcomes

  1. Arms A, B, and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the trial intervention. TEAEs are defined as AEs with start dates at the time of or following the first exposure to investigational medicinal product (IMP).

    Time frame: Up to Week 70

  2. Arms A, B, and C: Number of Participants With Related TEAEs

    A related AE is an AE that is considered related to the IMP. Related TEAEs are defined as related AEs with start dates at the time of or following the first exposure to IMP.

    Time frame: Up to Week 70

  3. Arms A, B, and C: Number of Participants With Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

    Time frame: Up to Week 70

  4. Arms A, B, and C: Number of Participants With AEs of Special Interest

    AEs of special interest are AEs that are considered specific to the IMP.

    Time frame: Up to Week 70

  5. Arms A, B, and C: Number of Participants With AE Leading to Treatment Discontinuation

    Time frame: Up to Week 70

  6. Arms A, B, and C: Number of Participants With Clinically Significant Abnormal Laboratory Test Results and Vital Signs

    Time frame: Up to Week 70

Secondary outcomes

  1. Arms A, B, and C: Percentage of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Weeks 24 and 48

    Achievement of biopsy-proven histological resolution of AMR activity will be assessed by the 2022 Banff classification criteria. The Banff 2022 Classification provides a standardized framework for evaluating kidney transplant biopsies using lesion scoring.

    Time frame: Weeks 24 and 48

  2. Arms A, B, and C: Microvascular Inflammation (MVI) Score in Biopsy Samples at Weeks 24 and 48

    MVI is an important marker of allograft loss and is defined as the sum of glomerulitis and peritubular capillaritis scores (g+ptc) on kidney histology.

    Time frame: Weeks 24 and 48

  3. Arms A, B, and C: Percentage of Participants Who Achieve a MVI Score of 0 at Weeks 24 and 48

    Time frame: Weeks 24 and 48

  4. Arms A, B, and C: Change From Baseline in MVI score at Weeks 24 and 48

    Time frame: Baseline, Weeks 24 and 48

  5. Arms A, B, and C: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 24, 48 and 70

    eGFR is a measure of kidney function calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

    Time frame: Baseline, Weeks 24, 48 and 70

  6. Arms A, B, and C: Change From Baseline in Donor-Derived Cell-Free DNA (dd-cfDNA) at Weeks 24, 48 and 70

    dd-cfDNA are DNA fragments released from injured donor cells. It serves as a noninvasive, quantitative method that reflects allograft injury and is associated with AMR activity in kidney transplant recipients.

    Time frame: Baseline, Weeks 24, 48 and 70

  7. Arms A, B, and C: Change From Baseline in Urine Protein Creatinine Ratio (UPCR) at Weeks 24, 48 and 70

    UPCR is a measure of protein excretion calculated from a urine sample, as the ratio of urine protein to creatinine, and used to assess kidney function.

    Time frame: Baseline, Weeks 24, 48 and 70

  8. Arm B: Percentage of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 70

    Time frame: Week 70

  9. Arm B: MVI Score in Biopsy Samples at Week 70

    Time frame: Week 70

  10. Arm B: Percentage of Participants Who Achieve a MVI Score of 0 at Week 70

    Time frame: Week 70

  11. Arm B: Change From Baseline in MVI score at Week 70

    Time frame: Week 70

  12. Arms A, B, and C: Percentage of Participants With T-Cell Mediated Rejection (TCMR) by Biopsy at Weeks 24 and 48

    Time frame: Weeks 24 and 48

  13. Arm B: Percentage of Participants With TCMR by Biopsy at Week 70

    Time frame: Week 70

  14. Arms A and B: Serum Concentration of Mezagitamab

    Time frame: Pre-dose and at multiple time points post-dose up to Week 70

  15. Arms A, B and C: Number of Participants With Anti-Drug Antibody

    Time frame: Pre-dose and at multiple time points post-dose up to Week 70

  16. Arms A, B and C: Number of Participants With Neutralizing Antibody

    Time frame: Pre-dose and at multiple time points post-dose up to Week 70

07

Study locations

4 of 35 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Jan 2029, 26 months after the start.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
Oct 27, 2026was Sep 2026
Primary completionEst.
Jan 15, 2029
CompletionEst.
Jan 15, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
35 sites changed recruiting status (31 now not yet recruiting, 4 now recruiting)
Show 35 sites
  • UCLA University of California Los Angeles · Los Angeles, United Statesno status→Not yet recruiting
  • Kaiser Permanente-San Francisco Medical Center - Kidney Transplant Clinic · San Francisco, United Statesno status→Not yet recruiting
  • University of Miami Hospital and Clinics · Miami, United Statesno status→Not yet recruiting
  • Tampa General Hospital · Tampa, United Statesno status→Not yet recruiting
  • University of Maryland · Baltimore, United Statesno status→Recruiting
  • Washington University School of Medicine · St Louis, United Statesno status→Not yet recruiting
  • Cooperman Barnabas Medical Center · Livingston, United Statesno status→Recruiting
  • NYU Langone Health - Transplant Associates · New York, United Statesno status→Not yet recruiting
  • Weill Cornell Medicine - Nephrology and Kidney Transplantation Medicine · New York, United Statesno status→Not yet recruiting
  • Cleveland Clinic - Cleveland · Cleveland, United Statesno status→Not yet recruiting
  • University of Texas Southwestern Medical Center · Dallas, United Statesno status→Not yet recruiting
  • Intermountain Healthcare · Murray, United Statesno status→Not yet recruiting
  • Virginia Commonwealth University (VCU) - Medical Center - Hume-Lee Transplant Center (HLTC) · Richmond, United Statesno status→Not yet recruiting
  • Froedtert and The Medical College of Wisconsin · Milwaukee, United Statesno status→Not yet recruiting
  • Beijing Friendship Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Sun Yat-sen University · Guangdong, Chinano status→Not yet recruiting
  • The Second Affiliated Hospital of Guangxi Medical University · Nanning, Chinano status→Not yet recruiting
  • Tongji Hospital Affiliated to Tongji Medicine University · Wuhan, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong University · Xi'an, Chinano status→Not yet recruiting
  • Shandong Provincial Qianfoshan Hospital · Jinan, Chinano status→Not yet recruiting
  • West China Hospital Sichuan University · Chengdu, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
  • CHU Bordeaux, CHU Pellegrin · Bordeaux, Franceno status→Not yet recruiting
  • Hopital Henri Mondor · Créteil, Franceno status→Not yet recruiting
  • Hopital Edouard Herriot (HEH) · Lyon, Franceno status→Not yet recruiting
  • CHU de Toulouse - Hopital Rangueil · Toulouse, Franceno status→Not yet recruiting
  • Kliniken Universitatsklinikum Bochum GmbH · Bochum, Germanyno status→Not yet recruiting
  • Universitaetsklinikum Essen · Essen, Germanyno status→Not yet recruiting
  • Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen · München, Germanyno status→Not yet recruiting
  • Universitaetsklinikum Muenster · Münster, Germanyno status→Not yet recruiting
  • …and 5 more on the registry record
Nov 6, 2026
Start date
Sep 1, 2026→Oct 27, 2026 (actual)
moved 2 times, Oct 1, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    35 sites changed recruiting status (31 now not yet recruiting, 4 now recruiting)
    Show 35 sites
    • UCLA University of California Los Angeles · Los Angeles, United Statesno status→Not yet recruiting
    • Kaiser Permanente-San Francisco Medical Center - Kidney Transplant Clinic · San Francisco, United Statesno status→Not yet recruiting
    • University of Miami Hospital and Clinics · Miami, United Statesno status→Not yet recruiting
    • Tampa General Hospital · Tampa, United Statesno status→Not yet recruiting
    • University of Maryland · Baltimore, United Statesno status→Recruiting
    • Washington University School of Medicine · St Louis, United Statesno status→Not yet recruiting
    • Cooperman Barnabas Medical Center · Livingston, United Statesno status→Recruiting
    • NYU Langone Health - Transplant Associates · New York, United Statesno status→Not yet recruiting
    • Weill Cornell Medicine - Nephrology and Kidney Transplantation Medicine · New York, United Statesno status→Not yet recruiting
    • Cleveland Clinic - Cleveland · Cleveland, United Statesno status→Not yet recruiting
    • University of Texas Southwestern Medical Center · Dallas, United Statesno status→Not yet recruiting
    • Intermountain Healthcare · Murray, United Statesno status→Not yet recruiting
    • Virginia Commonwealth University (VCU) - Medical Center - Hume-Lee Transplant Center (HLTC) · Richmond, United Statesno status→Not yet recruiting
    • Froedtert and The Medical College of Wisconsin · Milwaukee, United Statesno status→Not yet recruiting
    • Beijing Friendship Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Sun Yat-sen University · Guangdong, Chinano status→Not yet recruiting
    • The Second Affiliated Hospital of Guangxi Medical University · Nanning, Chinano status→Not yet recruiting
    • Tongji Hospital Affiliated to Tongji Medicine University · Wuhan, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Xi'an Jiaotong University · Xi'an, Chinano status→Not yet recruiting
    • Shandong Provincial Qianfoshan Hospital · Jinan, Chinano status→Not yet recruiting
    • West China Hospital Sichuan University · Chengdu, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
    • CHU Bordeaux, CHU Pellegrin · Bordeaux, Franceno status→Not yet recruiting
    • Hopital Henri Mondor · Créteil, Franceno status→Not yet recruiting
    • Hopital Edouard Herriot (HEH) · Lyon, Franceno status→Not yet recruiting
    • CHU de Toulouse - Hopital Rangueil · Toulouse, Franceno status→Not yet recruiting
    • Kliniken Universitatsklinikum Bochum GmbH · Bochum, Germanyno status→Not yet recruiting
    • Universitaetsklinikum Essen · Essen, Germanyno status→Not yet recruiting
    • Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen · München, Germanyno status→Not yet recruiting
    • Universitaetsklinikum Muenster · Münster, Germanyno status→Not yet recruiting
    • …and 5 more on the registry record
    Start date Oct 15, 2026→Oct 27, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 1, 2026
    Start date Sep 1, 2026→Oct 15, 2026
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07613359
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Oct 27, 2026
Primary completion
Jan 15, 2029 (estimated)
Completion
Jan 15, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezagitamab

Start the discussion